If your introduction to peptides came through Ozempic, Wegovy, or Mounjaro — you are in good company. The GLP-1 class brought peptides into mainstream conversation for the first time, and for millions of people it was the gateway to asking: "What else is out there?"
The short answer: Ozempic is technically a peptide, but it represents one specific, FDA-approved corner of a much larger and more varied field. Most research peptides are nothing like Ozempic in mechanism, legal status, or evidence base.
Here is how they actually relate.
What Ozempic is
Ozempic (semaglutide) is a GLP-1 receptor agonist — a synthetic peptide that mimics glucagon-like peptide-1, a hormone your gut produces naturally after eating. By activating GLP-1 receptors, it slows gastric emptying, reduces appetite, and stimulates insulin secretion. The result in clinical trials: significant and sustained weight reduction alongside improved blood sugar control.
Semaglutide has completed multiple Phase III randomized controlled trials with tens of thousands of participants. It received FDA approval for type 2 diabetes (Ozempic, 2017) and obesity (Wegovy, 2021). It is the most robustly evidenced weight loss compound ever approved.
What makes the GLP-1 class different from most research peptides
GLP-1 drugs like semaglutide and tirzepatide sit at the top of the evidence hierarchy — FDA approved, Phase III completed, available by prescription, dispensed by licensed pharmacies. This is the highest regulatory standard.
Most research peptides — BPC-157, TB-500, Semax, Epitalon — are nowhere near this standard. They have preclinical animal data, sometimes limited human studies, and are typically sold as research-use-only compounds without FDA approval. The evidence gap between Ozempic and BPC-157 is enormous — not because BPC-157 is necessarily ineffective, but because it has not been through the clinical trial process that would establish that either way.
The three GLP-1 compounds you will hear about
Semaglutide (Ozempic, Wegovy): FDA approved. The original mainstream GLP-1. Once-weekly injection. Approximately 15% average weight reduction in trials. Available by prescription. Compounding window largely closed as of 2026.
Tirzepatide (Mounjaro, Zepbound): FDA approved. Dual GLP-1/GIP agonist — slightly more effective than semaglutide in head-to-head data. Approximately 21% average weight reduction. Eli Lilly has aggressively pursued legal action against compounding pharmacies.
Retatrutide: Not FDA approved. Triple agonist targeting GLP-1, GIP, and glucagon simultaneously. Phase 2 data showed 24.2% weight reduction. Phase 3 trials ongoing. Highest legal risk of any GLP-1 adjacent compound — Eli Lilly actively litigating against vendors selling it as a research compound.
What the rest of the peptide world looks like
Beyond the GLP-1 class, research peptides fall into several different categories with completely different mechanisms and evidence bases:
Tissue repair compounds (BPC-157, TB-500): studied for healing injuries, gut lining repair, and inflammation reduction. Substantial animal data, limited human trials. Favorable PCAC recommendation July 2026.
GH axis peptides (Sermorelin, CJC-1295/Ipamorelin): stimulate the pituitary to release growth hormone. Sermorelin is FDA approved and widely compounded.
Cognitive peptides (Semax, Selank, Cerebrolysin): studied for neuroprotection, stroke recovery, and cognitive enhancement. Strongest evidence base in Cerebrolysin, which is approved in 45+ countries.
Longevity peptides (Epitalon, MOTS-c, SS-31): studied for cellular aging, telomere biology, and mitochondrial function. Mostly earlier-stage evidence.
Skin peptides (GHK-Cu, Argireline, Matrixyl): the best-tolerated and most accessible category — topical application, genuine clinical evidence for collagen synthesis and wound healing.
The bottom line
If Ozempic brought you here — welcome. You have arrived at the largest, most active moment in peptide research history. The PCAC just voted favorably on six research peptides in July 2026. Bloomberg just covered the space in a feature article. Searches for peptide information are up 500%+ year over year.
But understand that most of what you will find in this space is not Ozempic. The evidence varies enormously by compound. The legal status varies enormously by compound. Starting with the evidence tier and regulatory status of any specific compound is the responsible starting point.
See our full database for the evidence tier, legal status, and honest assessment of any compound you are curious about.